This study is testing a new treatment, AMG 510, for people with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC). This cancer is at stage IV (very advanced) or has come back (recurrent) and has a specific change in a gene called KRAS G12C. This change can make the cancer grow more, but AMG 510 is a special treatment targeting this change to help stop the cancer from growing. Patients take AMG 510 by mouth once a day for 21 days, and this cycle repeats. The study will check how well the treatment works and look for any side effects. Patients will have follow-up visits every 3 months for 3 years if the disease doesn't get worse. If it does, follow-ups are every 6 months for 2 years, then at the end of 3 years.

• **Study Length**: Ongoing cycles every 21 days, with follow-ups for up to 3 years.
• **Visits Needed**: Regular follow-ups even after treatment ends to check on progress.
• **Risks**: Possible side effects and need for close monitoring of health.